Evidence map›Paper›PMID 39763963›Full record

ArticlebioRxiv : the preprint server for biology2024

HIV-SEQ REVEALS GLOBAL HOST GENE EXPRESSION DIFFERENCES BETWEEN HIV-TRANSCRIBING CELLS FROM VIREMIC AND SUPPRESSED PEOPLE WITH HIV.

Julie Frouard, Sushama Telwatte, Xiaoyu Luo, Natalie Elphick, Reuben Thomas, Douglas Arneson, Pavitra Roychoudhury, Atul J Butte, Joseph K Wong, Rebecca Hoh and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Julie FrouardGladstone Institutes, San Francisco, CA 94158, USA.ORCID 0000-0002-6296-2534
Sushama TelwatteSan Francisco Veterans Affairs (VA) Medical Center and University of California, San Francisco, CA, USA.ORCID 0000-0003-4086-5212
Xiaoyu LuoGladstone Institutes, San Francisco, CA 94158, USA.ORCID 0000-0001-6059-0434
Natalie ElphickGladstone Institutes, San Francisco, CA 94158, USA.ORCID 0009-0006-3941-1095
Reuben ThomasGladstone Institutes, San Francisco, CA 94158, USA.
Douglas ArnesonBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9464-2586
Pavitra RoychoudhuryDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA; Viral and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.ORCID 0000-0002-4567-8232
Atul J ButteBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7433-2740
Joseph K WongSan Francisco Veterans Affairs (VA) Medical Center and University of California, San Francisco, CA, USA.ORCID 0000-0001-9896-0605
Rebecca HohDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, USA.
Steven G DeeksDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, USA.ORCID 0000-0001-6371-747X
Sulggi A LeeZuckerberg San Francisco General Hospital and the University of California, San Francisco, USA.ORCID 0000-0003-1560-2250
Nadia R RoanGladstone Institutes, San Francisco, CA 94158, USA.ORCID 0000-0002-5464-1976
Steven YuklSan Francisco Veterans Affairs (VA) Medical Center and University of California, San Francisco, CA, USA.ORCID 0000-0002-4578-9872

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
HOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Lishomwa C Ndhlovu, Melanie Maria Ott · 2021 to 2026
$32.2M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6M
The heterogeneous HIV expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to reboundP01AI169606 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Steven A Yukl · 2022 to 2026
$9.3M
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodesR01DK120387 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI LICHTERFELD, MATHIAS, YUKL, STEVEN A · 2019 to 2023
$4.1M
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologiesR01AI147777 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2019 to 2022
$3.8M
Multiomics characterization, induction, and elimination of the HIV gut reservoirR01DK131526 · NIDDK · J. DAVID GLADSTONE INSTITUTES · PI Nancie Marie Archin, Nadia R Roan · 2022 to 2026
$3.7M
Targeting the transcriptionally-active reservoir to reduce chronic inflammation in aged people with HIVR01AI183286 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Melanie Maria Ott, Nadia R Roan · 2024 to 2026
$2.7M
Understanding HIV latency reversal and clearance of infected cells in vivoR01AI132128 · NIAID · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WONG, JOSEPH K, YUKL, STEVEN A · 2017 to 2021
$1.9M
Single-cell Analysis of Glycomic and Proteomic Features of the HIV ReservoirR21AI170166 · NIAID · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED, ROAN, NADIA R · 2022 to 2023
$530k
NIAID NIH HHS P01 AI169606NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI132128NIAID NIH HHS R01 AI147777NIAID NIH HHS R01 AI183286NIAID NIH HHS R21 AI170166NIAID NIH HHS UM1 AI164559NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164567NIDDK NIH HHS R01 DK120387NIDDK NIH HHS R01 DK131526
6 · The paper itself

Abstract

"Active" reservoir cells transcribing HIV can perpetuate chronic inflammation in virally suppressed people with HIV (PWH) and likely contribute to viral rebound after antiretroviral therapy (ART) interruption, so they represent an important target for new therapies. These cells, however, are difficult to study using single-cell RNA-seq (scRNA-seq) due to their low frequency and low levels of HIV transcripts, which are usually not polyadenylated. Here, we developed "HIV-seq" to enable more efficient capture of HIV transcripts - including non-polyadenylated ones - for scRNA-seq analysis of cells from PWH. By spiking in a set of custom-designed capture sequences targeting conserved regions of the HIV genome during scRNA-seq, we increased our ability to find HIV RNA+ cells from PWH by up to 44%. Implementing HIV-seq in conjunction with surface phenotyping by CITE-seq on paired blood specimens from PWH before vs. after ART suppression, we found that HIV RNA+ cells were enriched among T effector memory (Tem) cells during both viremia and ART suppression, but exhibited a cytotoxic signature during viremia only. By contrast, HIV RNA+ cells from the ART-suppressed timepoints exhibited a distinct anti-inflammatory signature involving elevated TGF-β and diminished IFN signaling. Overall, these findings demonstrate that active reservoir cells exhibit transcriptional features distinct from HIV RNA+ cells during viremia, and underscore HIV-seq as a useful tool to better understand the mechanisms by which HIV-transcribing cells can persist during ART.

Identifiers

PMID39763963
PMCPMC11702770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.